MA47208A - Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 - Google Patents
Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1Info
- Publication number
- MA47208A MA47208A MA047208A MA47208A MA47208A MA 47208 A MA47208 A MA 47208A MA 047208 A MA047208 A MA 047208A MA 47208 A MA47208 A MA 47208A MA 47208 A MA47208 A MA 47208A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- cancer treatment
- treatment methods
- cancer
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762444336P | 2017-01-09 | 2017-01-09 | |
US201762477423P | 2017-03-27 | 2017-03-27 | |
US201762491220P | 2017-04-27 | 2017-04-27 | |
US201762556386P | 2017-09-09 | 2017-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47208A true MA47208A (fr) | 2019-11-13 |
Family
ID=61188903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047208A MA47208A (fr) | 2017-01-09 | 2018-01-09 | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 |
Country Status (21)
Country | Link |
---|---|
US (2) | US11407830B2 (fr) |
EP (2) | EP4219563A3 (fr) |
JP (2) | JP7110206B6 (fr) |
KR (1) | KR102606252B1 (fr) |
CN (1) | CN110382545A (fr) |
AU (1) | AU2018206481A1 (fr) |
BR (1) | BR112019014187A2 (fr) |
CA (1) | CA3049440A1 (fr) |
DK (1) | DK3565844T3 (fr) |
ES (1) | ES2945745T3 (fr) |
FI (1) | FI3565844T3 (fr) |
HU (1) | HUE061842T2 (fr) |
IL (1) | IL267804A (fr) |
MA (1) | MA47208A (fr) |
MX (1) | MX2019008207A (fr) |
PL (1) | PL3565844T3 (fr) |
PT (1) | PT3565844T (fr) |
SG (2) | SG10201913075RA (fr) |
TW (1) | TWI767976B (fr) |
WO (1) | WO2018129559A1 (fr) |
ZA (1) | ZA201904316B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201402815VA (en) | 2008-04-09 | 2014-09-26 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
TW202246349A (zh) | 2016-10-11 | 2022-12-01 | 美商艾吉納斯公司 | 抗lag-3抗體及其使用方法 |
CA3041684C (fr) * | 2016-11-01 | 2023-09-26 | Anaptysbio, Inc. | Anticorps diriges contre la mort programmee 1 (pd -1) |
EP4219563A3 (fr) | 2017-01-09 | 2023-10-04 | Tesaro, Inc. | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 |
BR112019024135A2 (pt) | 2017-05-18 | 2020-06-02 | Tesaro, Inc. | Terapias de combinação para o tratamento de câncer |
US11730725B2 (en) | 2017-09-26 | 2023-08-22 | Tesaro, Inc. | Niraparib formulations |
BR112020006286A2 (pt) | 2017-09-30 | 2020-10-20 | Tesaro, Inc. | terapias de combinação para tratamento do câncer |
MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
TW202024638A (zh) * | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | 治療癌症之方法 |
KR20210071022A (ko) | 2018-10-03 | 2021-06-15 | 테사로, 인코포레이티드 | 니라파립 염 |
US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
US20200199567A1 (en) * | 2018-12-20 | 2020-06-25 | Medimmune, Llc | Methods for selection and expansion of t cells expressing pd-1 |
WO2020243338A1 (fr) * | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Méthodes de traitement du cancer avec une protéine de fusion sirpalpha-fc en association avec un inhibiteur de point de contrôle immunitaire |
US20230059341A1 (en) | 2019-12-18 | 2023-02-23 | Tesaro, Inc. | Biopharmaceutical compositions and related methods |
EP4085908A4 (fr) * | 2019-12-31 | 2024-01-17 | Fukang Shanghai Health Tech Co Ltd | Combinaison pharmaceutique destinée à traiter des tumeurs et son application |
WO2021152495A1 (fr) | 2020-01-28 | 2021-08-05 | Glaxosmithkline Intellectual Property Development Limited | Traitements combinés et utilisations et méthodes associées |
EP4060346A4 (fr) * | 2020-02-18 | 2023-12-13 | Innobation Bio Co., Ltd. | Composition de biomarqueur de diagnostic compagnon et kit de diagnostic compagnon la contenant |
EP4168118A1 (fr) * | 2020-06-18 | 2023-04-26 | Genentech, Inc. | Traitement avec des anticorps anti-tigit et des antagonistes de liaison à l'axe pd-1 |
WO2022025482A1 (fr) * | 2020-07-29 | 2022-02-03 | 재단법인 아산사회복지재단 | Composition pour la prévention et le traitement du cancer colorectal, comprenant de la streptonigrine et un inhibiteur de point de contrôle immunitaire en tant que principes actifs |
WO2023076668A1 (fr) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions et méthodes de traitement du cancer |
WO2023153763A1 (fr) * | 2022-02-08 | 2023-08-17 | 고려대학교 산학협력단 | Vaccin contre le cancer comprenant un épitope de c-met et un épitope de hif1alpha, et son utilisation |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
EP0557459B1 (fr) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Genes de fusion selectionnables bifonctionnels |
EP0804590A1 (fr) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd) |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US6808710B1 (en) | 1999-08-23 | 2004-10-26 | Genetics Institute, Inc. | Downmodulating an immune response with multivalent antibodies to PD-1 |
WO2002000730A2 (fr) | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Molecules pd-l2 : nouveaux ligands de pd-1 et utilisations de ceux-ci |
FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
KR20030066657A (ko) | 2000-11-15 | 2003-08-09 | 오노 야꾸힝 고교 가부시키가이샤 | Pd-1 결손 마우스 및 그 용도 |
AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
WO2002079499A1 (fr) | 2001-04-02 | 2002-10-10 | Wyeth | Le pd-1, recepteur du b7-4, et ses utilisations |
ATE524495T1 (de) | 2001-07-31 | 2011-09-15 | Ono Pharmaceutical Co | Pd-1-spezifische substanz |
WO2003042402A2 (fr) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents modulant l'activite de cellules immunes et procedes d'utilisation associes |
FI2206517T3 (fi) | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
ES2729974T3 (es) | 2003-01-23 | 2019-11-07 | Ono Pharmaceutical Co | Anticuerpo específico de PD-1 y CD3 humanas |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
RU2596491C2 (ru) | 2005-06-08 | 2016-09-10 | Дана-Фарбер Кэнсер Инститьют | Способы и композиции для лечения персистирующих инфекций |
EP2937360A1 (fr) | 2005-06-17 | 2015-10-28 | Merck Sharp & Dohme Corp. | Molécules se liant à l'ilt3 et leurs utilisations |
US8216996B2 (en) | 2006-03-03 | 2012-07-10 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
KR20150002879A (ko) * | 2006-10-02 | 2015-01-07 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
CN101663323A (zh) | 2006-12-27 | 2010-03-03 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
EP2126105A4 (fr) | 2007-02-20 | 2010-11-03 | Anaptysbio Inc | Systèmes d'hypermutation somatique |
WO2008115732A2 (fr) | 2007-03-20 | 2008-09-25 | Eli Lilly And Company | Anticorps antisclérostine |
CN103626875B (zh) | 2007-05-30 | 2016-01-13 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US20120269806A1 (en) | 2007-08-21 | 2012-10-25 | The General Hospital Corporation | Methods of inducing tolerance |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
CN106008460B (zh) | 2008-01-08 | 2022-08-12 | 默沙东公司 | 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 |
EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
JP5945096B2 (ja) | 2008-07-04 | 2016-07-05 | 小野薬品工業株式会社 | 抗ヒトpd−1抗体の癌に対する治療効果を最適化するための判定マーカーの使用 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
WO2010029434A1 (fr) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Anticorps spécifiques de pd-1 et leurs utilisations |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
DK2370593T3 (en) | 2008-11-28 | 2016-07-04 | Univ Emory | A method for determining the effect of PD-1 Antagonists |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
CN102782149B (zh) * | 2009-11-04 | 2014-11-12 | 默沙东公司 | 经工程改造的抗-tslp抗体 |
SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
CA2790134A1 (fr) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Modulation de pd-1 et utilisations de celle-ci pour moduler la replication du vih |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
JP5920929B2 (ja) | 2010-03-11 | 2016-05-18 | ユセベ ファルマ ソシエテ アノニム | Pd−1抗体 |
US20110256135A1 (en) * | 2010-03-17 | 2011-10-20 | Wolfgang Fraunhofer | Anti-nerve growth factor (ngf) antibody compositions |
CA2793309A1 (fr) | 2010-03-17 | 2011-09-22 | Anaptysbio, Inc. | Procede de production de produits de la transcription utilisant des sites cryptiques d'epissage |
JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのtim−3およびpd−1に対する二重特異性抗体 |
CA2805564A1 (fr) | 2010-08-05 | 2012-02-09 | Stefan Jenewein | Proteine de fusion anticorps anti-cmh cytokine antivirale |
US20130217656A1 (en) | 2010-08-12 | 2013-08-22 | Beth Israel Deaconess Medical Center Inc | Methods and compositions for diagnosing and treating lupus |
US20130310266A1 (en) | 2010-09-03 | 2013-11-21 | Immport Therapeutics, Inc. | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders |
EP2910572B1 (fr) | 2010-11-11 | 2017-09-06 | Versitech Limited | Variants solubles pd-1, structures de fusion et utilisations de ceux-ci |
CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
CN103429264A (zh) | 2011-03-31 | 2013-12-04 | 默沙东公司 | 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗 |
TWI496886B (zh) | 2011-06-24 | 2015-08-21 | Taipei Veteran General Hospital | 提升感染性與惡性疾病之治療之免疫反應 |
ES2893855T3 (es) | 2011-08-11 | 2022-02-10 | Ono Pharmaceutical Co | Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1 |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
WO2013169693A1 (fr) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Méthodes destinées à traiter le cancer à l'aide d'un polypeptide il-21 et d'un anticorps anti-pd-1 |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
US20150079192A1 (en) | 2012-05-21 | 2015-03-19 | Marv Enterprises, LLC | Treatment of cancer by manipulating the immune system |
WO2013174997A1 (fr) | 2012-05-25 | 2013-11-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de malignités hématologiques réfractaires |
EP3556776A1 (fr) | 2012-05-31 | 2019-10-23 | F. Hoffmann-La Roche AG | Procédés de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'antagonistes de vegf |
RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
RS59480B1 (sr) | 2013-12-12 | 2019-12-31 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
US20170088626A1 (en) * | 2014-03-05 | 2017-03-30 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
US11059898B2 (en) | 2014-03-24 | 2021-07-13 | Cancer Research Technology Limited | Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof |
BR112016029650A2 (pt) | 2014-06-19 | 2017-10-24 | Regeneron Pharma | roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor? |
PT3177644T (pt) | 2014-08-05 | 2021-01-13 | MabQuest SA | Reagentes imunológicos que se ligam a pd-1 |
US20170247455A1 (en) * | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
AU2015338974B2 (en) | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
MA41217A (fr) | 2014-12-19 | 2017-10-24 | Advaxis Inc | Polythérapies ayant des souches de listeria recombinées |
EP3233918A1 (fr) | 2014-12-19 | 2017-10-25 | Novartis AG | Polythérapies |
US10239942B2 (en) | 2014-12-22 | 2019-03-26 | Pd-1 Acquisition Group, Llc | Anti-PD-1 antibodies |
PT3240801T (pt) | 2014-12-31 | 2021-02-18 | Checkmate Pharmaceuticals Inc | Imunoterapia antitumoral combinada |
EP3244925A4 (fr) | 2015-01-16 | 2018-06-06 | Academia Sinica | Constructions moléculaires avec éléments de ciblage et effecteur |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
TN2017000440A1 (en) * | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
WO2016176504A1 (fr) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Traitement du mélanome pd-l1 positif à l'aide d'un anticorps anti-pd-1 |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
PT3478286T (pt) | 2016-06-29 | 2024-01-31 | Tesaro Inc | Métodos de tratamento do cancro do ovário |
CA3041684C (fr) * | 2016-11-01 | 2023-09-26 | Anaptysbio, Inc. | Anticorps diriges contre la mort programmee 1 (pd -1) |
TW201825512A (zh) | 2016-11-29 | 2018-07-16 | 美商提薩羅有限公司 | 針對計劃性死亡-1(pd-1)之抗體 |
EP4219563A3 (fr) | 2017-01-09 | 2023-10-04 | Tesaro, Inc. | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 |
MA47206A (fr) | 2017-01-09 | 2019-11-13 | Tesaro Inc | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
BR112020006286A2 (pt) | 2017-09-30 | 2020-10-20 | Tesaro, Inc. | terapias de combinação para tratamento do câncer |
-
2018
- 2018-01-09 EP EP23158731.2A patent/EP4219563A3/fr active Pending
- 2018-01-09 BR BR112019014187-1A patent/BR112019014187A2/pt unknown
- 2018-01-09 MX MX2019008207A patent/MX2019008207A/es unknown
- 2018-01-09 HU HUE18704101A patent/HUE061842T2/hu unknown
- 2018-01-09 CN CN201880016132.XA patent/CN110382545A/zh active Pending
- 2018-01-09 JP JP2019537103A patent/JP7110206B6/ja active Active
- 2018-01-09 AU AU2018206481A patent/AU2018206481A1/en active Pending
- 2018-01-09 PT PT187041017T patent/PT3565844T/pt unknown
- 2018-01-09 TW TW107100822A patent/TWI767976B/zh active
- 2018-01-09 SG SG10201913075RA patent/SG10201913075RA/en unknown
- 2018-01-09 EP EP18704101.7A patent/EP3565844B8/fr active Active
- 2018-01-09 WO PCT/US2018/013029 patent/WO2018129559A1/fr unknown
- 2018-01-09 SG SG11201906192SA patent/SG11201906192SA/en unknown
- 2018-01-09 KR KR1020197023407A patent/KR102606252B1/ko active IP Right Grant
- 2018-01-09 US US16/476,536 patent/US11407830B2/en active Active
- 2018-01-09 MA MA047208A patent/MA47208A/fr unknown
- 2018-01-09 DK DK18704101.7T patent/DK3565844T3/da active
- 2018-01-09 PL PL18704101.7T patent/PL3565844T3/pl unknown
- 2018-01-09 CA CA3049440A patent/CA3049440A1/fr active Pending
- 2018-01-09 ES ES18704101T patent/ES2945745T3/es active Active
- 2018-01-09 FI FIEP18704101.7T patent/FI3565844T3/fi active
-
2019
- 2019-06-28 ZA ZA2019/04316A patent/ZA201904316B/en unknown
- 2019-07-02 IL IL267804A patent/IL267804A/en unknown
-
2022
- 2022-04-11 JP JP2022065095A patent/JP2022082809A/ja active Pending
- 2022-07-15 US US17/812,933 patent/US20230111418A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4219563A2 (fr) | 2023-08-02 |
ES2945745T3 (es) | 2023-07-06 |
TW201831200A (zh) | 2018-09-01 |
FI3565844T3 (fi) | 2023-05-09 |
EP3565844A1 (fr) | 2019-11-13 |
DK3565844T3 (da) | 2023-05-01 |
WO2018129559A1 (fr) | 2018-07-12 |
US20230111418A1 (en) | 2023-04-13 |
JP7110206B2 (ja) | 2022-08-01 |
BR112019014187A2 (pt) | 2020-02-11 |
JP7110206B6 (ja) | 2022-08-25 |
PL3565844T3 (pl) | 2023-06-12 |
CA3049440A1 (fr) | 2018-07-12 |
CN110382545A (zh) | 2019-10-25 |
JP2022082809A (ja) | 2022-06-02 |
MX2019008207A (es) | 2019-12-11 |
EP3565844B1 (fr) | 2023-03-01 |
SG11201906192SA (en) | 2019-08-27 |
KR20190114996A (ko) | 2019-10-10 |
AU2018206481A1 (en) | 2019-07-25 |
US11407830B2 (en) | 2022-08-09 |
US20200239574A1 (en) | 2020-07-30 |
JP2020504141A (ja) | 2020-02-06 |
ZA201904316B (en) | 2022-12-21 |
EP3565844B8 (fr) | 2023-04-12 |
IL267804A (en) | 2019-09-26 |
PT3565844T (pt) | 2023-05-02 |
SG10201913075RA (en) | 2020-02-27 |
TWI767976B (zh) | 2022-06-21 |
EP4219563A3 (fr) | 2023-10-04 |
KR102606252B1 (ko) | 2023-11-23 |
HUE061842T2 (hu) | 2023-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47208A (fr) | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
MA45192A (fr) | Traitement d'association | |
MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
CU24498B1 (es) | Anticuerpos de factor xi | |
MA43197A (fr) | Constructions d'anticorps bispécifiques pour cdh3 et cd3 | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA51306A (fr) | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase | |
MA47613A (fr) | Compositions et procédés de traitement du cancer | |
MA41375A (fr) | Anticorps igg bispécifiques et leurs procédés de préparation |